The Predictive Value of SPP1 Gene Expression for the Survival of Advanced Liver Cancer Treated with Transarterial Chemoembolization

Objective: To evaluate the predictive value of secreted phosphoprotein 1 (SPP1) gene expression for postoperative survival in patients with advanced liver cancer undergoing hepatic artery interventional chemoembolization treatment. Method: Bioinformatics methods, including gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, were used to identify genes related to survival prognosis in hepatocellular carcinoma (HCC) patients. A retrospective analysis of 115 advanced liver cancer patients treated between January 2016 and October 2017 was conducted. Patients were categorized into SPP1 high-expression (n = 89) and low-expression groups (n = 26). Additionally, 115 healthy individuals served as the control group. The relationship between SPP1 expression and clinical pathological features was analyzed. A 60-month follow-up and logistic regression analysis identified risk factors affecting survival. Results: SPP1 mRNA expression was significantly higher in liver cancer patients compared to healthy controls (P < 0.05). SPP1 expression levels were significantly associated with tumor size, Child-Pugh grading, lymph node metastasis, and BCLC staging (P < 0.05). High SPP1 expression, along with tumor size, Child-Pugh grading, lymph node metastasis, and BCLC staging, were independent risk factors for survival (P < 0.05). The 60-month survival rate was 17.39%, with a median survival of 40 months in the low-expression group versus 18 months in the high-expression group (P < 0.05). Conclusion: SPP1 expression is significantly upregulated in advanced liver cancer patients and has predictive value for postoperative survival following hepatic artery chemoembolization treatment. SPP1, combined with clinical indicators such as tumor size, Child-Pugh grading, lymph node metastasis, and BCLC staging, may serve as a prognostic biomarker for interventional treatment outcomes.

Authors

Institutions

Publication Details

Journal
Proceedings of Anticancer Research
Published
2025-02-13
DOI
https://doi.org/10.26689/par.v9i1.9360
Primary Topic
Cancer, Lipids, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Predictive Value of SPP1 Gene Expression for the Survival of Advanced Liver Cancer Treated with Transarterial Chemoembolization

Yuqing Li, Siqi Wang, Yuanyuan Jia, Chang Tian et al.
Proceedings of Anticancer Research
Cancer, Lipids, and Metabolism
article

The Predictive Value of SPP1 Gene Expression for the Survival of Advanced Liver Cancer Treated with Transarterial Chemoembolization

Yuqing Li, Siqi Wang, Yuanyuan Jia, Chang Tian, Yu Cai, Pu Yan
article en

Abstract

Objective: To evaluate the predictive value of secreted phosphoprotein 1 (SPP1) gene expression for postoperative survival in patients with advanced liver cancer undergoing hepatic artery interventional chemoembolization treatment. Method: Bioinformatics methods, including gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, were used to identify genes related to survival prognosis in hepatocellular carcinoma (HCC) patients. A retrospective analysis of 115 advanced liver cancer patients treated between January 2016 and October 2017 was conducted. Patients were categorized into SPP1 high-expression (n = 89) and low-expression groups (n = 26). Additionally, 115 healthy individuals served as the control group. The relationship between SPP1 expression and clinical pathological features was analyzed. A 60-month follow-up and logistic regression analysis identified risk factors affecting survival. Results: SPP1 mRNA expression was significantly higher in liver cancer patients compared to healthy controls (P < 0.05). SPP1 expression levels were significantly associated with tumor size, Child-Pugh grading, lymph node metastasis, and BCLC staging (P < 0.05). High SPP1 expression, along with tumor size, Child-Pugh grading, lymph node metastasis, and BCLC staging, were independent risk factors for survival (P < 0.05). The 60-month survival rate was 17.39%, with a median survival of 40 months in the low-expression group versus 18 months in the high-expression group (P < 0.05). Conclusion: SPP1 expression is significantly upregulated in advanced liver cancer patients and has predictive value for postoperative survival following hepatic artery chemoembolization treatment. SPP1, combined with clinical indicators such as tumor size, Child-Pugh grading, lymph node metastasis, and BCLC staging, may serve as a prognostic biomarker for interventional treatment outcomes.

Proceedings of Anticancer ResearchVol. 9(1)
Xi'an Medical University (CN)
Yakult Bio-Science Foundation, Key Research and Development Projects of Shaanxi Province
Good health and well-being
Openalex Percentile: Top 97%
Cancer, Lipids, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.